Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IP Group plc ( (GB:IPO) ) has provided an update.
IP Group has flagged a likely writedown in the value of its stake in Pulmocide after the portfolio company terminated its Opera-T Phase 3 trial of the antifungal treatment opelconazole in patients with refractory invasive pulmonary aspergillosis. Pulmocide, in which IP Group holds a 12% interest currently valued at £28.1m, will now review the unblinded trial data to assess future options for the programme, while IP Group plans a significant reduction in the asset’s carrying value as part of its year-end process but maintains that its broader pipeline of new and maturing investments and licence portfolio underpins its confidence in delivering medium-term returns for shareholders.
The most recent analyst rating on (GB:IPO) stock is a Hold with a £59.00 price target. To see the full list of analyst forecasts on IP Group plc stock, see the GB:IPO Stock Forecast page.
Spark’s Take on GB:IPO Stock
According to Spark, TipRanks’ AI Analyst, GB:IPO is a Neutral.
The score is held back primarily by weak financial performance (recent losses and negative cash flow), with limited valuation support from a negative P/E. Mixed technicals suggest no strong momentum tailwind, while the latest earnings call provides a moderate offset via improved cash proceeds, NAV stabilization, and management confidence in exit targets despite portfolio-specific setbacks.
To see Spark’s full report on GB:IPO stock, click here.
More about IP Group plc
IP Group plc is a London-listed investor focused on early-stage science and innovation businesses across deeptech, life sciences and cleantech. As the most active UK-based early-stage science investor, it backs emerging technologies from leading universities and research institutions, including through its Parkwalk growth EIS funds, and has supported high-profile companies such as Oxford Nanopore Technologies, Featurespace, First Light Fusion, Hysata and Oxa.
Average Trading Volume: 3,950,856
Technical Sentiment Signal: Hold
Current Market Cap: £525.6M
For an in-depth examination of IPO stock, go to TipRanks’ Overview page.